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Hepatocellular carcinoma (HCC) is a primary liver malignancy and accounts for most of the total liver cancer cases. Lack of
treatment options and late diagnosis contribute to high mortality rate of HCC. In eukaryotes, translation of messenger RNA
(mRNA) to protein is a key process in protein biosynthesis in which initiation of translation involves interaction of different
eukaryotic translation initiation factors (eIFs), ribosome subunits and mRNAs. Eukaryotic translation initiation factor 5A (eIF5A)
is one of the eIFs involved in translation initiation and eIF5A2, one of its isoforms, is upregulated in various cancers including
HCC as a result of chromosomal instability, where it resides. In HCC, eIF5A2 expression is associated with adverse prognosis such
as presence of tumor metastasis and venous infiltration. Based on eIF5A2 functional studies, suppressing eIF5A2 expression by
short interfering RNA alleviates the tumorigenic properties of HCC cells in vitro while ectopic expression of eIF5A2 enhances the
aggressiveness of HCC cells in vivo and in vitro by inducing epithelial-mesenchymal transition. In conclusion, eIF5A2 is a potential
prognostic marker as well as a therapeutic target for HCC.
1. Clinical Situation of Liver Cancer
Liver cancer is one of the most prevalent and lethal
malignancies worldwide. It is the secondmost frequent cause
of cancer deaths and the fifth most common diagnosed
cancer in men. Liver cancer is prevalent in Southeast Asia
and Africa, but the incidence rates are also on the rise
in America and Europe. The number of incident cases
worldwide is over 740,000 per year, and the number of
mortality cases is similar to the incident cases. Hepatocellular
carcinoma (HCC) represents the major subtype of primary
liver cancer, accounting for 70–85% of total liver cancer
cases [1]. High-risk population of HCC includes cirrhosis
patients and hepatitis B or C virus carriers. Other risk
factors include aflatoxin intake, obesity, and alcohol abuse
[2]. The high mortality rate of HCC is a result of lack
of treatment options and late diagnosis. A few commonly
used diagnostic methods for HCC include ultrasonography
and detection of alpha-fetoprotein in the serum. Early stage
HCC is often asymptomatic, and most HCCs are diagnosed
at an advanced stage where treatment options are limited.
Currently, curative treatment options for patients diagnosed
with early stage HCC include surgical resection of tumor
and liver transplantation. However, surgical resection results
in a high rate of postsurgical recurrence, and it is not
suitable for patients with impaired liver functions. While
for liver transplantation, shortage of liver grafts remains
a major challenge. Another treatment option for HCC
patients is transarterial chemoembolization (TACE). TACE
is a minimally invasive procedure where blood flow to
the tumor is blocked and chemotherapeutic agents are
administered directly to the tumor. However, patients with
impaired liver function are not suitable for TACE treatment
as it may lead to severe complications due to liver failure
[2]. Targeted therapy offers an alternative for advanced
stage HCC patients who are not suitable for curative
treatments or TACE. Sorafenib, the only FDA-approved
targeted therapy for the treatment of advanced HCC, is
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a multikinase inhibitor targeting several different kinases
including vascular endothelial growth factor receptor and
platelet-derived growth factor receptor. It is also the only
systematic agent found to increase the survival time of
patients by about 3 months. However, in addition to its
restricted use in advanced HCC, it cannot be administered
to HCC patients with severe cardiovascular disease and
portal hypertension [3, 4]. Based on the current clinical
situation of HCC, lack of effective treatment options is a
major factor leading to the high mortality rate of HCC.
Thus, it is necessary to develop new treatments that can be
used for HCC patients under a wide range of conditions.
Based on our previous study and other studies, it is proposed
that eukaryotic translation initiation factors (eIFs) constitute
a potential class of therapeutic targets for treatment of
various cancers, and this paper will focus on discussing the
implications of using eukaryotic translation initiation factor
5A (eIF5A) as a prognostic marker and treatment target in
HCC.
2. Protein Synthesis and eIFs
In eukaryotes, translation of messenger RNA (mRNA) to a
polypeptide is a key process in protein synthesis. It consists of
three main steps: (1) initiation of translation, (2) elongation
of polypeptide chain, and (3) termination of translation. In
brief, the initiation step involves the assembly of different
ribosomal subunits, initiation factors, and mRNA to form
an 80S ribosomal complex. Transfer RNAs (tRNAs), carrying
specific amino acids, recognize the codon of mRNA and
bind to the 80S ribosomal complex to start the initiation
step. As the ribosomal complex moves along the mRNA,
different tRNAs recognize their corresponding codon and
bring amino acids to the ribosomal complex to form a
polypeptide chain. The translation process terminates when
the ribosomal complex encounters a termination signal.
This termination codon cannot be recognized by tRNAs.
The polypeptide chain is then released from the ribosomal
complex and proceeds to posttranslational modification
while the 80S ribosomal complex disassembles and recycles
again [5–9].
The eIF family represents a group of proteins that are
involved in the initiation step of protein translation. Each
member plays a unique role in the initiation process by
interacting with ribosomal subunits and mRNAs to form
an elongation competent complex [6]. There are at least ten
different eIFs taking part in the initiation step of translation,
which involves eIF interaction with mRNA, 40S and 60S
ribosomal subunits to form an 80S ribosomal complex. In
brief, eIF4A, eIF4B, eIF4E, and eIF4G activate mRNA while
eIF1, eIF1A, eIF2, eIF3, and eIF5 interact with 40S and
60S ribosomal subunits. The activated mRNA subsequently
binds to the 40S and 60S subunits to form the 80S ribosomal
complex, which initiates translation [6, 8, 9]. The following
sections will discuss the protein synthesis pathway and in
particular the protein translation control process in cancer
development.
3. Deregulation of Protein Synthesis
Pathway Frequently Observed in Cancers
Total protein levels in cells are regulated by two cellular
mechanisms, the ubiquitin system and the protein synthesis
mechanism. It is well known that the ubiquitin-mediated
degradation of protein is important for regulating different
cellular activities such as transcription, signal transduction
and cell-cycle progression [10–13], while protein synthesis
is vital for protein generation and determination of cellular
phenotype. Under normal conditions, the protein synthesis
pathway is well regulated to prevent overproduction of
proteins. However, aberrant activation of this pathway, such
as those associated with mammalian target of rapamycin
(mTOR), is observed in various cancers, leading to uncon-
trolled protein synthesis and the subsequent transformation
of normal cells to more aggressive cancerous cells [14, 15].
Dysregulation of cellular signaling pathways is one of the
hallmarks of cancer [16, 17]. For example, the mitogen-
activated protein kinase (MAPK) [18] and the phosphoinosi-
tide 3-kinase (PI3 K)-Akt [19, 20] pathways are constitutively
activated in various cancers. These pathways regulate cel-
lular activities such as proliferation and differentiation but
accumulative mutations impair the regulatory mechanism of
these pathways that render cells with growth and survival
advantages. Dysregulation of the protein synthesis pathway,
similar to other deregulated signaling pathways, sometimes
is a result of accumulative mutations in a cell. For example,
deregulation can be caused by aberrant expression of eIFs
together with aberrant activation of mTOR signaling path-
way [7]. It has been suggested that restoring the aberrant
activated pathway may inhibit cell transformation. However,
further research is warranted to support this idea. It is found
that there are different eIFs aberrantly expressed in liver
tumors (Table 1), the content below will focus on one eIF
family member, eIF5A, which is a unique member of the
protein synthesis pathway and has been reported to have an
oncogenic role in cancer development.
4. eIF5A and Its Isoforms
eIF5A is a small molecular-sized protein classified in the
eIF family. It is conserved in all organisms from bacteria
to humans, except in eubacteria. eIF5A mainly functions as
an elongation factor in mRNA translation by facilitating the
formation of the first peptide bond during the translation
initiation step. eIF5A also serves as a shuttle protein regu-
lating the nucleus-cytoplasmic transport of mRNAs in cells
[24–26]. eIF5A is the only protein in eukaryotes to contain
the amino acid residue hypusine. Hypusine, [Nε-(4-amino-
2-hydroxybutyl)lysine], is a polyamine-derived amino acid
which is formed by the post-translational modification of
lysine in a process known as hypusination. This is a two-step
enzymatic reaction which activates eIF5A. In the first step,
the deoxyhypusine synthase (DHS) catalyzes the transfer
of the 4-aminobutyl moiety of spermidine to the lysine
residue (Lys50) of eIF5A precursor (inactive form) to form
an intermediate, deoxyhypusine residue. This intermediate
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Table 1: Differential expression of different eIFs in liver tumors.
Eukaryotic translation initiation
factor (eIF)
Expression level
Clinical correlation with high
level of eIF
References
eIF3S3 Induction
Large tumor size,
presence of HBV infection
[21]
eIF4A1 Induction NS [22]
eIF4E Induction Increased tumor invasiveness [22, 23]
NS: not studied.
is sequentially hydroxylated by the enzyme deoxyhypusine
hydroxylase (DOHH) to form a hypusine residue to complete
the process [25, 27]. The eIF5A precursor is activated by
hypusination and converted to a functional mature eIF5A.
eIF5A is important in translation initiation since disruption
of hypusination process by the DHS inhibitor, N1-guanyl-
1,7-diaminoheptane (GC7), has been shown to inhibit
growth of endothelial cells [28].
In humans, two isoforms of eIF5A have been identified
sharing 80% cDNA sequence and 94% protein similar-
ity [29, 30]. eIF5A1 is predominantly expressed in most
mammalian cells, whereas eIF5A2 is differentially expressed
in specific tissues such as testis and brain [30, 31]. The
genes encoding isoforms eIF5A1 and eIF5A2 are located on
different chromosomes, suggesting their different functional
roles. The eIF5A1 gene resides on chromosome 17p12-p13
whereas eIF5A2 gene resides on chromosome 3q25-q27, a
region where amplification is observed in different human
malignancies [32–36]. Therefore, eIF5A2 has been proposed
as an oncogene which could contribute to carcinogenesis and
tumor progression, suggesting further research on the roles
of eIF5A2 in HCC.
5. Aberrant Expression of eIF5A Isoforms in
HCC and Other Cancers
Various approaches have been used to study the genomic
and proteomic profile of cancer cells. Differential expression
of the two eIF5A isoforms has been observed in different
cancers (Table 2). It is suggested that up-regulation of eIF5A
expression contributes to proliferation of cancer cells most
likely by constitutive activation of the protein synthesis
pathway. In HCC, eIF5A2 is aberrantly expressed at mRNA
and protein levels, whereas no change in expression level
of eIF5A1 has been observed. In addition, tissues with up-
regulation of eIF5A2 also show high levels of DHS and
DOHH at the transcript level [37], indicating constitutive
activation of eIF5A2 synthesis and hypusination resulting in
increased protein synthesis and cell growth in HCC. Utilizing
comparative genomic hybridization and copy number vari-
ation analysis, chromosome 3q is amplified in HCC [38],
as well as in several cancers including pancreatic [36, 39],
esophageal [40, 41], prostate [42], lung [32, 43], gastric
[44, 45], ovarian [33, 46] and colorectal [30, 47] cancer.
Thus, the aberrant expression of eIF5A2, also residing on
chromosome 3q, is more frequently observed than that of
eIF5A1 and this may at least partially explain for the aberrant
expression of eIF5A2 in HCC. In addition, chromosome 3q
amplification has also been correlated to HCC recurrence
[48]. Thus, the role of eIF5A2 in HCC recurrence warrants
further research.
Aberrant expression of the two eIF5A isoforms is
reported in various cancers other than HCC. It is demon-
strated that there is an up-regulation of eIF5A1 in colorectal
adenoma by comparing the proteomic profiles of colorectal
adenoma and normal mucosa using 2-dimensional elec-
trophoresis proteomic profiling [49]. In ovarian cancer,
eIF5A2 overexpression promotes tumorigenesis both in vitro
and in vivo and is also positively correlated to an advanced
stage of the disease [46]. In a recent study of non-small
cell lung cancer (NSCLC), He et al. reported up-regulation
of eIF5A2 in about 40% of tumor tissues by immunohisto-
chemistry. This aberrant expression of eIF5A2 was positively
correlated with advanced tumor stage and also indicated
poor prognosis for early stage NSCLC patients. Furthermore,
fluorescence in situ hybridization demonstrated amplifica-
tion of eIF5A2 gene in NSCLC tumors. Therefore, up-
regulation of eIF5A2 may result from genetic instability of
chromosome 3q and may serve as a prognostic marker for
early stage NSCLC [51].
Based on the above studies, we postulated that the dif-
ferential expression and function of the two eIF5A isoforms
are contributed partially by genetic instability of cancer cells.
eIF5A1 gene resides on a genetically stable chromosome
whose aberrant expression in cancers is not frequent. In addi-
tion, eIF5A1 is expressed in most mammalian cells implying
that the function of eIF5A1 is to maintain basal level of
mRNA translation in cells. While for eIF5A2, the gene resides
on a genetically unstable chromosome whose amplification
is frequently observed in various cancers. Chromosome 3q
amplification leads to up-regulation of eIF5A2 in cancers,
disturbing the well-regulated translational level maintained
by eIF5A1 and leading to aberrant activation of protein
synthesis pathway; as the result, normal cells are transformed
to more aggressive cancerous cells.
6. Prognostic Implications of eIF5A
Isoforms in HCC
This section will describe and discuss the correlation of
eIF5A isoforms and clinical characteristics of HCC. Using
cDNA microarray analysis, Lee et al. found an association
between high levels of eIF5A1 and eIF5A2 with increased
number of tumor nodules and presence of venous infil-
tration, respectively, in patients [37]. In consistence with
these findings, another study using quantitative polymerase
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Table 2: Aberrant expression of eIF5A1 and eIF5A2 in different human cancers.
Malignancy
Expression in tumor Chromosome 3q Clinical correlation with References
eIF5A1 eIF5A2 amplification high eIF5A level
Colorectal cancer Induction Induction Presence NS [30, 47, 49]
Esophageal cancer NS Induction Presence NS [40, 41]
Gastric cancer NS NS Presence NS [44, 45]
Liver cancer Unchanged Induction Presence
Increased number of tumor
nodules,
presence of tumor venous
infiltration
[37, 38, 48,
50]
Lung cancer NS Induction Presence
Advanced tumor stage, poor
survival of patients
[32, 43, 51]
Ovarian cancer NS Induction Presence Advanced tumor stage [33, 46]
Pancreatic cancer NS Induction Presence NS [36, 39, 52]
Prostate cancer NS NS Presence NS [42]
NS: not studied.
chain reaction reported a reciprocal association between up-
regulation of eIF5A2 with tumor metastasis and encapsu-
lation [50]. These results suggest the differential roles of
eIF5A1 and eIF5A2 in HCC development. Aberrant mRNA
expression of eIF5A1 promotes the formation of tumor
nodules, whereas up-regulation of eIF5A2 mRNA indicates
adverse prognosis in HCC, as its expression may predict
metastasis and tumor invasion. However, as a cytoplasmic
protein, eIF5A2 expression can only be assessed at the
mRNA level or by intracellular localization. It would also
be clinically significant, for ease of diagnosis and minimal
invasion, if a secretory form of eIF5A2 can be identified
in patient serum or blood, but until now, this has not
been reported in any malignancy. Although eIF5A1 mRNA
expression is similar in liver tumor and non-tumor tissues,
its expression is positively correlated to the number of tumor
nodules in HCC. Thus, a combined analysis of eIF5A1
with other HCC tumor growth markers may improve its
prognostic potential.
7. Therapeutic Potential of Targeting
eIF5A2 in HCC
Given their association to different clinical characteristics
of HCC, it is of interest to study the therapeutic potential
of eIF5A isoforms for HCC treatment. Several studies have
investigated the role of eIF5A2 as a potential therapeu-
tic target for HCC. Loss-of-function study by Lee et al.
demonstrated inhibition of cell growth and reduction of cell
migration in HCC cells upon suppression of eIF5A2 using
short interfering RNA (siRNA)[37]. Further demonstrating
this, Tang et al. reported by a gain-of-function study in
which overexpression of eIF5A2 in HCC cells promotes
cell migration in vitro and tumorigenicity in vivo. Addi-
tionally, ectopic expression of eIF5A2 induced epithelial-
mesenchymal transition, characterized by the downregula-
tion of epithelial markers, β-catenin and E-cadherin, and
up-regulation of mesenchymal markers including vimentin
and N-cadherin. Moreover, overexpression of eIF5A2 also
induced Rho/Rac GTPases activity to facilitate reorgani-
zation of actin cytoskeleton and disruption of adherent
junctions [50]. Together these studies demonstrate the
potential of eIF5A2 siRNA treatment as an adjuvant therapy
for HCC patients. Antibody treatment offers an alternative
to targeting eIF5A2 but currently there is no report of
eIF5A2 antibody therapy in HCC. Other than targeting
eIF5A2 alone, the effectiveness of combined therapy has
also been investigated. Combined treatment of eIF5A2
siRNA and GC7, an inhibitor of DHS, on HCC cells
resulted in a synergistic inhibition of cell migration [50].
As described in the previous section, inhibition of DHS
activity by GC7 disrupts the hypusination process, abol-
ishing eIF5A2 activation and leading to eIF5A precursor
accumulation in cells [28, 31]. Further studies are warranted
to investigate the effectiveness of combined treatment in
vivo for the development of eIF5A2-targeted therapy in
HCC.
8. Summary
In summary, eIF5A, an indispensable member of the transla-
tion initiation process, is found to be aberrantly expressed in
different malignancies including HCC, ovarian cancer, and
lung cancer. One of its isoforms, eIF5A2, is overexpressed in
HCC tissues, and this up-regulation may be a result of chro-
mosome 3q amplification where the eIF5A2 gene resides.
Clinical studies have demonstrated a correlation between
up-regulation of eIF5A2 level with tumor metastasis and
venous infiltration. Therefore, eIF5A2 has been proposed
as an indicator of tumor invasiveness in HCC. In addition,
targeting eIF5A2 by siRNA and combined treatment with
GC7 effectively reduces the migration ability of tumor cells,
suggesting that targeting eIF5A2 and hypusination could be
a potential treatment for HCC.
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